Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1988 Apr;63(4):663–668.

Inhibition of tumour necrosis factor and natural cytotoxic cell lytic activities by a spleen cell-elaborated factor.

Y Lin 1, P G Case 1, P Q Patek 1
PMCID: PMC1454795  PMID: 3366472

Abstract

Natural cytotoxic (NC) cell lytic activity is mediated by tumour necrosis factor (TNF), a protein with potent cytolytic activity on certain target cells. TNF also appears to mediate a wide range of other important biological activities (e.g. interferon-like anti-viral activity, induction of granulocyte-monocyte colony-stimulating factor, mediation of endotoxin-induced shock). Evidence is presented here that spleen cells from normal, untreated mice produce a factor(s) that inhibits both NC and TNF cytolytic activity. The factor(s) has a molecular weight greater than 10,000. Since indomethacin inhibits production by spleen cells of the NC/TNF inhibitory factor, it is suggested that prostaglandins are involved in the regulation of its production. Additionally, these studies indicate that the factor(s) does not function by inactivation of either NC effectors or TNF molecules, or by inhibition of the binding of NC cells or TNF to targets. Instead, the data suggest that the factor(s) acts on the targets rendering them refractory to TNF binding. Moreover, since the factor(s) acts slowly and requires protein synthesis in the target to function, it appears that the inhibitory activity is mediated via de novo-synthesized proteins from the target cells. At present, it is not known whether such a factor functions in vivo, although it is conceivable that its in vivo role is to modulate the pathological potential of TNF by protecting certain cells from NC or TNF lysis.

Full text

PDF
663

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  2. Broudy V. C., Kaushansky K., Segal G. M., Harlan J. M., Adamson J. W. Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7467–7471. doi: 10.1073/pnas.83.19.7467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brunda M. J., Herberman R. B., Holden H. T. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol. 1980 Jun;124(6):2682–2687. [PubMed] [Google Scholar]
  4. Bykowsky M. J., Stutman O. The cells responsible for murine natural cytotoxic (NC) activity: a multi-lineage system. J Immunol. 1986 Aug 15;137(4):1120–1126. [PubMed] [Google Scholar]
  5. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Collins J. L., Patek P. Q., Cohn M. Tumorigenicity and lysis by natural killers. J Exp Med. 1981 Jan 1;153(1):89–106. doi: 10.1084/jem.153.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Epstein R., Cohn M. T-cell inhibition of humoral responsiveness. I. Experimental evidence for restriction by the K- and/or D-end of the H-2 gene complex. Cell Immunol. 1978 Aug;39(1):110–124. doi: 10.1016/0008-8749(78)90088-6. [DOI] [PubMed] [Google Scholar]
  8. Gersten M. J., Cohn M. A defined basal medium for study of in vitro T-cell responses. Cell Immunol. 1985 Mar;91(1):143–158. doi: 10.1016/0008-8749(85)90039-5. [DOI] [PubMed] [Google Scholar]
  9. Hudig D., Djobadze M., Redelman D., Mendelsohn J. Active tumor cell resistance to human natural killer lymphocyte attack. Cancer Res. 1981 Jul;41(7):2803–2808. [PubMed] [Google Scholar]
  10. Lin Y., Collins J. L., Patek P. Q., Cohn M. An analysis of the sensitivity of somatic cell hybrids to natural killer cell- and natural cytotoxic cell-mediated lysis. J Immunol. 1983 Sep;131(3):1154–1159. [PubMed] [Google Scholar]
  11. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D., Möller A., Jacobsen H., Kirchner H. Antiviral effects of recombinant tumour necrosis factor in vitro. 1986 Oct 30-Nov 5Nature. 323(6091):816–819. doi: 10.1038/323816a0. [DOI] [PubMed] [Google Scholar]
  12. Miyamoto T., Yamamoto S., Hayaishi O. Prostaglandin synthetase system--resolution into oxygenase and isomerase components. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3645–3648. doi: 10.1073/pnas.71.9.3645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ortaldo J. R., Mason L. H., Mathieson B. J., Liang S. M., Flick D. A., Herberman R. B. Mediation of mouse natural cytotoxic activity by tumour necrosis factor. Nature. 1986 Jun 12;321(6071):700–702. doi: 10.1038/321700a0. [DOI] [PubMed] [Google Scholar]
  15. Patek P. Q., Collins J. L., Cohn M. Evidence that cytotoxic T cells and natural cytotoxic cells use different lytic mechanisms to lyse the same targets. Eur J Immunol. 1983 May;13(5):433–436. doi: 10.1002/eji.1830130516. [DOI] [PubMed] [Google Scholar]
  16. Patek P. Q., Lin Y., Collins J. L., Cohn M. In vivo or in vitro selection for resistance to natural cytotoxic cell lysis selects for variants with increased tumorigenicity. J Immunol. 1986 Jan;136(2):741–745. [PubMed] [Google Scholar]
  17. Patek P. Q., Lin Y., Collins J. L. Natural cytotoxic cells and tumor necrosis factor activate similar lytic mechanisms. J Immunol. 1987 Mar 1;138(5):1641–1646. [PubMed] [Google Scholar]
  18. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  19. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  20. Trinchieri G., Kobayashi M., Rosen M., Loudon R., Murphy M., Perussia B. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med. 1986 Oct 1;164(4):1206–1225. doi: 10.1084/jem.164.4.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Vilcek J., Palombella V. J., Henriksen-DeStefano D., Swenson C., Feinman R., Hirai M., Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med. 1986 Mar 1;163(3):632–643. doi: 10.1084/jem.163.3.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wong G. H., Goeddel D. V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. 1986 Oct 30-Nov 5Nature. 323(6091):819–822. doi: 10.1038/323819a0. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES